Leerink notes that Intellia Therapeutics (NTLA) announced a protocol-specified pause of Phase 3 MAGNITUDE and MAGNITUDE-2 studies of nex-z in ATTR, following report of G4 liver transaminases and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback